Search Result

Results for "

clot

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Autophagy (2) Bacterial (2) Biochemical Assay Reagents (1) Cytochrome P450 (3) Endogenous Metabolite (3) Factor VIIa (2) Factor Xa (12) Interleukin Related (1) Isotope-Labeled Compounds (2) NF-κB (1) P2Y Receptor (6) PAI-1 (2) Prostaglandin Receptor (1) Proteasome (2) SARS-CoV (1) Sirtuin (5) Syk (1) Thrombin (6)
By Research Areas:	Cancer (17) Cardiovascular Disease (32) Infection (2) Inflammation/Immunology (10) Metabolic Disease (15) Neurological Disease (5)
Oligonucleotides:	Aptamers (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W040030

Hematin	Others	Metabolic Disease Cancer
Hematin, an iron-containing porphyrin, inhibits the activity of clotting factors and also fibrin clot lysis through the mechanism of binding to and inactivation of hemostatic proteins . Hematin can be used for the research of acute porphyrias and cancer .

HY-125864

Fibrinogen (Bovine)	Interleukin Related NF-κB	Inflammation/Immunology
Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-B1560

Bismuth subgallate 1 Publications Verification	Factor Xa	Others
Bismuth subgallate, a hemostatic agent, acts on coagulation factor XII (Hageman factor), leading to the activation of the coagulation cascade and improving early formation of a fibrin clot .

HY-P2373

Nattokinase, Natto fermentation 1 Publications Verification	Others	Cardiovascular Disease
Nattokinase, Natto fermentation is a potent fibrinolytic enzyme. Nattokinase can break down blood clots by directly hydrolyzing fibrin and plasmin substrate. Nattokinase can be used for the research of cardiovascular diseases .

HY-108883

Plasmin, Human plasma Fibrinolysins, Human plasma; Serum tryptase, Human plasma; TAL 05-00018, Human plasma	Others	Inflammation/Immunology
Plasmin, Human plasma is an important protease present in blood that degrades many plasma proteins, including fibrin clots. Plasmin can also act as a potent regulator of the immune process and can directly interact with various cell types, including monocytes, macrophages, and dendritic cells .

HY-P2824

Streptokinase, β-hemolytic streptococcus (Lancefield Group C)	Others	Cardiovascular Disease
Streptokinase, β-hemolytic streptococcus (Lancefield Group C) is a bacteria-derived protein and a plasminogen activator. Streptokinase is widely used for the research of the blood-clotting disorders. Streptokinase improves reperfusion blood flow after coronary artery occlusion .

HY-E70393A

Human Factor IXa Beta	Others	Metabolic Disease
Human Factor IXa Beta is composed of two polypeptide chains held together by disulfide bonds. Human Factor IXa Beta shows clotting activity .

HY-113164

Vitamin K1 2,3-epoxide	Endogenous Metabolite	Others
Vitamin K1 2,3-epoxide is an inactive metabolite form of Vitamin K1 (HY-N0684), which is reduced to active vitamin by microsomal epoxide reductase in the vitamin K epoxide cycle. Vitamin K1 2,3-epoxide is involved in blood clotting .

HY-109549

Desirudin CGP 39393; Revasc	Thrombin	Cardiovascular Disease
Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction .

HY-P4721

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated)	Thrombin	Cardiovascular Disease
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a K_D < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .

HY-B0236

6-Aminocaproic acid 2 Publications Verification EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid	Others	Metabolic Disease Cancer
6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-118284

Vicagrel 1 Publications Verification	P2Y Receptor	Cardiovascular Disease
Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .

HY-17459

Clopidogrel hydrogen sulfate Maximum Cited Publications 20 Publications Verification (S)-(+)-Clopidogrel bisulfate; (S)-(+)-Clopidogrel hydrogen sulfate	Cytochrome P450 P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC₅₀s of 18.2 nM and 524 nM, respectively . Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation ．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor .

HY-156023

Sirtuin modulator 7	Sirtuin	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sirtuin modulator 7 is a sirtuin-modulating compound which may increase the lifespan of a cell, and may be used for research of diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and flushing which would benefit from increased mitochondrial activity .

HY-E70393H

Human Factor XIIIa	Others	Others
Human Factor XIIIa is a transglutaminase, which catalyzes the cross-linking of proteins and stabilizes the blood clots. Human Factor XIIIa protects the clots from degradation by fibrinolytic enzymes, which is important for maintaining hemostasis and preventing excessive bleeding .

HY-148322

Sirtuin modulator 5	Sirtuin	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sirtuin modulator 5 is a sirtuin modulating agent. Sirtuin modulator 5 can activate SIRT1 with a DC₅₀ value of <50 μM. Sirtuin modulator 5 can be used for increasing the lifespan of a cell and used for the research of variety of diseases including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity .

HY-B2172

Vitamin K	Endogenous Metabolite	Cardiovascular Disease
Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.

HY-153480

ARC19499 BAX499	Factor Xa	Others
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-153480A

ARC19499 sodium BAX499 sodium	Factor Xa Factor VIIa	Others
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-B0665

Fibrin	Others	Cardiovascular Disease Cancer
Fibrin, isolated from bovine blood, is an insoluble protein produced in response to bleeding. Fibrin is the major component of the blood clot and is used for coagulation .

HY-120491

L 722151	Others	Cardiovascular Disease
L 722151 is a competitive inhibitor for factor XIIIa with K_i of 49 µM. L 722151 accelerates tissue plasminogen activator-catalyzed clot dissolution, and exhibits antithrombotic efficacy .

HY-147393

Factor VII-IN-1	Others	Cardiovascular Disease
Factor VII-IN-1 (example 43) is a potent inhibitor of factor VII (FVII), with an IC₅₀ of 1.1 μM. Factor VII-IN-1 shows anticoagulant properties .

HY-B1181

Hydrastinine hydrochloride	Others	Cardiovascular Disease
Hydrastinine hydrochloride is a major alkaloid constituent in goldenseal (Hydrastis canadensis). Hydrastinine hydrochloride can be used as a haemostatic agent .

HY-B1181A

Hydrastinine	Others	Cardiovascular Disease
Hydrastinine is a major alkaloid constituent in goldenseal (Hydrastis canadensis). Hydrastinine can be used as a haemostatic agent .

HY-15283

Clopidogrel Maximum Cited Publications 20 Publications Verification Clopidogrelum	P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

HY-120980

Thromboxane B1 TXB1	Prostaglandin Receptor	Cardiovascular Disease
Thromboxane B1 (TXB1) is one of thromboxane B (TXB) family members. Thromboxane is a member of the family of lipids known as eicosanoids. Thromboxane is named for its role in blood clot formation (thrombosis) .

HY-E70393D

Human Factor Alpha XIIa	Others	Others
Human Factor Alpha XIIa is a blood coagulation protease, which increases the clotting potential. Human Factor Alpha XIIa exhibits a fibrinolysis protein homologous heavy chain, indicating its function in fibrinolysis .

HY-117724

AZ3976	PAI-1	Cardiovascular Disease
AZ3976 is a potent plasminogen activator inhibitor type 1 (PAI-1) inhibitor with an IC₅₀ value of 26 μM in an enzymatic chromogenic assay. AZ3976 is active with an IC₅₀ of 16 μM in a plasma clot lysis assay. AZ3976 does not bind to active PAI-1 but bound reversibly to latent PAI-1. AZ3976 inhibits PAI-1 by enhancing the latency transition of active PAI-1. AZ3976 displays profibrinolytic activities in a human plasma clot lysis assay .

HY-14854

Tecarfarin ATI-5923	Others	Cardiovascular Disease
Tecarfarin (ATI-5923) is an orally active and non-competitive vitamin K epoxide reductase (VKOR) antagonist, and impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin has the antithrombotic activity .

HY-10787

Ximelagatran 1 Publications Verification H 376/95	Thrombin	Cardiovascular Disease
Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics .

HY-14854A

Tecarfarin sodium ATI-5923 sodium	Others	Metabolic Disease
Tecarfarin sodium (ATI-5923 sodium) is a novel orally active non-competitive vitamin K epoxide reductase (VKOR) antagonist, impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X . Tecarfarin sodium has the antithrombotic activity .

HY-15283R

Clopidogrel (Standard)	P2Y Receptor	Cardiovascular Disease Cancer
Clopidogrel (Standard) is the analytical standard of Clopidogrel. This product is intended for research and analytical applications. Clopidogrel is an orally active platelet inhibitor that targets P2Y12 receptor. Clopidogrel is used to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

HY-107966

Heparin calcium (MW 15000-19000) Nadroparin calcium (MW 15000-19000)	Thrombin Factor Xa Autophagy Bacterial	Cardiovascular Disease Cancer
Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-107966A

Heparin calcium (MW 3600-5000) Nadroparin calcium (MW 3600-5000)	Thrombin Factor Xa Autophagy Bacterial	Cardiovascular Disease Cancer
Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-12586

AZD6564	Others	Others
AZD6564 is an orally active inhibitor for fibrinolysis through disruption of plasma kinase-fibrin interaction. AZD6564 dissolves human plasma clot with an IC₅₀ of 0.44 μM. AZD6564 ameliorates hemorrhage in rats with EC₅₀ of 1.62 μM, and exhibits good pharmacokinetic characteristics in rats .

HY-124577

MDI-2268	PAI-1	Cardiovascular Disease
MDI-2268 is an inhibitor of plasma kallikrein inhibitor 1 (PAI-1). MDI-2268 has good antithrombotic properties and regulates blood coagulation and fibrinolysis process by enhancing fibrinolysis. MDI-2268 can be used in research areas such as deep vein thrombosis .

HY-130587

Sultosilic acid piperazine salt Piperazine sultosylate; A-585	Others	Metabolic Disease
Sultosilic acid piperazine salt (Piperazine sultosylate; A-585) is a lipid-lowering agent. Sultosilic acid piperazine salt modifies the blood lipids levels, reduces platelet adhesiveness without promoting peroxisomal activity of hepatocytes or producing other adverse side-effects .

HY-E70393

Human Factor VIIa	Factor VIIa	Others
Human Factor VIIa is a vitamin K-dependent serine protease that is involved in the blood coagulation process. Human Factor VIIa activates Factor X, which causes the conversion of prothrombin to thrombin and the conversion of fibrinogen to fibrin, leading to the formation of blood clots. Human Factor VIIa exhibits the potential to ameliorate Hemophilia .

HY-117290

BMS-962212	Factor Xa	Cardiovascular Disease
BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity .

HY-107785

2-Deoxy-2-sulfoamino-D-glucose sodium D-Glucosamine-2-N-sulfate sodium	Endogenous Metabolite	Metabolic Disease
2-Deoxy-2-sulfoamino-D-glucose sodium (D-Glucosamine-2-N-sulfate sodium) is an endogenous metabolite. The main regulatory mechanism of 2-Deoxy-2-sulfoamino-D-glucose sodium involves the interaction of sulfuric acid groups with biomolecules. Sulfate groups can influence the charge density and configuration of polysaccharides, thereby regulating their ability to bind to proteins such as antithrombin. This combination can enhance the activity of antithrombin, which in turn inhibits key enzymes in the blood clotting process to achieve anti-clotting effects. 2-Deoxy-2-sulfoamino-D-glucose sodium can be used to study the selective removal of n-sulfate groups from Heparin (HY-17567) which has important implications for understanding the biological activity of heparin and developing related drugs .

HY-B0236A

6-Aminocaproic acid hydrochloride EACA hydrochloride; Epsilon-Amino-n-caproic Acid hydrochloride; 6-Aminohexanoic acid hydrochloride	Others	Metabolic Disease Cancer
6-Aminocaproic acid hydrochloride, a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-E70393E

Human Factor XIIa Beta	Others	Others
Human Factor XIIa Beta is the active fragment of coagulation factor XII, that participates in the intrinsic pathway of coagulation, and leads to the formation of blood clots. Human Factor XIIa Beta also participates in the kinin-generating pathway, which leads to the release of bradykinin (vasodilator). Human Factor XIIa Beta stimulates the release of catecholamines, and mediates its cardiovascular effects through a noncholinergic angiotensin-converting enzyme (ACE)-regulated mechanism .

HY-50667R

Apixaban (Standard)	Factor Xa	Cardiovascular Disease Cancer
Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-50667

Apixaban 5+ Cited Publications BMS-562247-01	Factor Xa	Cardiovascular Disease Cancer
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-50667S

Apixaban-13C,d3 BMS-562247-01-¹³C,d₃	Factor Xa	Cardiovascular Disease
Apixaban- ¹³C,d₃ is a deuterium and ¹³C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].

HY-N7314

Asebogenin	Syk	Inflammation/Immunology
Asebogenin has antimalarial activity in vitro . Asebogenin can inhibit the phosphorylation of Syk, thereby effectively suppressing platelet activation and the formation of neutrophil extracellular traps .

HY-113958

Difethialone LM-2219	Others	Others
Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .

HY-B0236S1

6-Aminocaproic acid-d10 EACA-d₁₀; Epsilon-Amino-n-caproic Acid-d₁₀; 6-Aminohexanoic acid-d₁₀	Isotope-Labeled Compounds	Metabolic Disease
6-Aminocaproic acid-d₁₀ is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

HY-B0236S

6-Aminocaproic acid-d6 EACA-d₆; Epsilon-Amino-n-caproic acid-d₆; 6-Aminohexanoic acid-d₆	Isotope-Labeled Compounds	Metabolic Disease
6-Aminocaproic acid-d₆ is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

HY-B0385

Gabexate mesylate 4 Publications Verification FOY	Proteasome Factor Xa	Inflammation/Immunology
Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with K_is of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with K_is of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .

Cat. No.	Product Name

HY-L136

Coagulation and Anti-coagulation Compound Library

1,025 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,025 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Cat. No.	Product Name	Type

HY-125864

Fibrinogen (Bovine)

Native Proteins

Fibrinogen (Bovine) is a selective proteolytic molecule that can be activated by thrombin to assemble fibrin clots. Fibrinogen can regulate the activation of NF-KB in endothelial cells and upregulate the expression of inflammatory chemokines MCP-1 and MCP-1. Fibrinogen plays a key role in blood clotting, thrombosis, atherosclerosis and the pathological development of venous grafts, and can be used in the study of blood clotting and vascular diseases .

HY-125139

omega-3 Arachidonic acid ethyl ester, in ethanol, 98%

ω-3 Arachidonic acid ethyl ester, in ethanol, 98%; (all-Z)-8,11,14,17-Eicosatetraenoic acid ethyl ester, in ethanol, 98%

Drug Delivery

omega-3 Arachidonic acid ethyl ester, in ethanol, 98% is a rare polyunsaturated fatty acid found in very small amounts in dietary sources. Omega-3 fatty acids are known to be essential for the growth and development of infants, and they protect against heart disease, blood clots, high blood pressure, and inflammatory and autoimmune diseases. In human platelet membranes, omega-3 arachidonic acid inhibits arachidonyl-CoA synthetase with a Ki of 14 μM. It also inhibits arachidonoyl-CoA synthetase in calf brain extract with an IC50 of approximately 5 μM. Omega-3 ethyl arachidonate is the more lipophilic form of the free acid.

HY-107966

Heparin calcium (MW 15000-19000) Nadroparin calcium (MW 15000-19000)	Cell Assay Reagents
Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-107966A

Heparin calcium (MW 3600-5000) Nadroparin calcium (MW 3600-5000)	Cell Assay Reagents
Heparin (Nadroparin) calcium (MW 3600-5000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin .

HY-107785

2-Deoxy-2-sulfoamino-D-glucose sodium

D-Glucosamine-2-N-sulfate sodium

Carbohydrates

2-Deoxy-2-sulfoamino-D-glucose sodium (D-Glucosamine-2-N-sulfate sodium) is an endogenous metabolite. The main regulatory mechanism of 2-Deoxy-2-sulfoamino-D-glucose sodium involves the interaction of sulfuric acid groups with biomolecules. Sulfate groups can influence the charge density and configuration of polysaccharides, thereby regulating their ability to bind to proteins such as antithrombin. This combination can enhance the activity of antithrombin, which in turn inhibits key enzymes in the blood clotting process to achieve anti-clotting effects. 2-Deoxy-2-sulfoamino-D-glucose sodium can be used to study the selective removal of n-sulfate groups from Heparin (HY-17567) which has important implications for understanding the biological activity of heparin and developing related drugs .

Cat. No.	Product Name	Target	Research Area

HY-P4721

Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated)	Thrombin	Cardiovascular Disease
Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is a hirugen-like peptide, and has high affnity for thrombin than Hirugen, with a K_D < 100 nM. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) is an antithrombotic agent. Succinyl-(Pro58,D-Glu65)-Hirudin (56-65) (sulfated) inhibits the thrombin-induced fibrin clot formation with an IC50 value of 0.087 μM .

HY-P10045

Integrin signaling inhibitor, mP13	Peptides	Cardiovascular Disease
Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .

HY-P5356

H-D-Val-Leu-Lys-AFC Plasmin substrate	Peptides	Others
H-D-Val-Leu-Lys-AFC (Plasmin substrate) is a biological active peptide. (This is a fluorescent plasmin substrate, Abs/Em=380/500 nm.Plasmin belongs to the family of serine proteases. It plays a key role in fibrinolysis by dissolving fibrin in blood clots. Besides fibrinolysis, plasmin is also involved in such physiological and pathological processes as wound healing, liver repair, and the maintenance of liver homeostasis.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0236

6-Aminocaproic acid 2 Publications Verification EACA; Epsilon-Amino-n-caproic Acid; 6-Aminohexanoic acid	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Others
6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders .

HY-B2172

Vitamin K	Cardiovascular Disease Natural Products other families Microorganisms Classification of Application Fields Animals Source classification Plants Disease Research Fields	Endogenous Metabolite
Vitamin K, the blood-clotting vitamin, is important for the function of numerous proteins within the body, such as the coagulation factors, osteocalcin and matrix-Gla protein.

HY-B0665

Fibrin	Cardiovascular Disease Natural Products Animals Source classification Disease Research Fields Cancer	Others
Fibrin, isolated from bovine blood, is an insoluble protein produced in response to bleeding. Fibrin is the major component of the blood clot and is used for coagulation .

HY-B1181

Hydrastinine hydrochloride	Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Guttiferae Ranunculaceae Source classification Plants Isoquinoline Alkaloids Disease Research Fields Hypericum monogynum L.	Others
Hydrastinine hydrochloride is a major alkaloid constituent in goldenseal (Hydrastis canadensis). Hydrastinine hydrochloride can be used as a haemostatic agent .

HY-B1181A

Hydrastinine	Cardiovascular Disease Alkaloids Classification of Application Fields Source classification Ranunculaceae Plants Isoquinoline Alkaloids Disease Research Fields	Others
Hydrastinine is a major alkaloid constituent in goldenseal (Hydrastis canadensis). Hydrastinine can be used as a haemostatic agent .

HY-107785

2-Deoxy-2-sulfoamino-D-glucose sodium D-Glucosamine-2-N-sulfate sodium	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Saccharides	Endogenous Metabolite
2-Deoxy-2-sulfoamino-D-glucose sodium (D-Glucosamine-2-N-sulfate sodium) is an endogenous metabolite. The main regulatory mechanism of 2-Deoxy-2-sulfoamino-D-glucose sodium involves the interaction of sulfuric acid groups with biomolecules. Sulfate groups can influence the charge density and configuration of polysaccharides, thereby regulating their ability to bind to proteins such as antithrombin. This combination can enhance the activity of antithrombin, which in turn inhibits key enzymes in the blood clotting process to achieve anti-clotting effects. 2-Deoxy-2-sulfoamino-D-glucose sodium can be used to study the selective removal of n-sulfate groups from Heparin (HY-17567) which has important implications for understanding the biological activity of heparin and developing related drugs .

HY-N7314

Asebogenin	Structural Classification Populus balsamifera L. Source classification Phenols Polyphenols Plants Salicaceae	Syk
Asebogenin has antimalarial activity in vitro . Asebogenin can inhibit the phosphorylation of Syk, thereby effectively suppressing platelet activation and the formation of neutrophil extracellular traps .

Cat. No.	Product Name	Chemical Structure

HY-50667S

Apixaban-13C,d3
Apixaban- ¹³C,d₃ is a deuterium and ¹³C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].

HY-B0236S

6-Aminocaproic acid-d6

6-Aminocaproic acid-d₆ is deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

HY-B0236S1

6-Aminocaproic acid-d10

6-Aminocaproic acid-d₁₀ is the deuterium labeled 6-Aminocaproic acid. 6-Aminocaproic acid (EACA), a monoamino carboxylic acid, is a potent and orally active inhibitor of plasmin and plasminogen. 6-Aminocaproic acid is a potent antifibrinolytic agent. 6-Aminocaproic acid prevents clot lysis through the competitive binding of lysine residues on plasminogen, inhibiting plasmin formation and reducing fibrinolysis. 6-Aminocaproic acid can be used for the research of bleeding disorders[1][2].

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

Cat. No.	Product Name		Classification

HY-153480A

ARC19499 sodium BAX499 sodium		Aptamers
ARC19499 sodium is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 sodium blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 sodium corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

HY-153480

ARC19499 BAX499		Aptamers
ARC19499 is an aptamer that inhibits tissue factor pathway inhibitor (TFPI) , thereby enabling clot initiation and propagation via the extrinsic pathway. The core aptamer binds tightly and specifically to TFPI. ARC19499 blocks TFPI inhibition of both factor Xa and the TF/factor VIIa complex. ARC19499 corrects thrombin generation in hemophilia A and B plasma and restores clotting in FVIII-neutralized whole blood.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

clot

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products